Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis

Richard Castillo, Ngoc Pham, Edward Castillo, Samantha Aso-Gonzalez, Sobiya Ansari, Brian Hobbs, Diana Palacio, Heath Skinner, Thomas M. Guerrero

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Purpose: To examine the association between pre-radiation therapy (RT) fluorine 18 fluorodeoxyglucose (FDG) uptake and post-RT symptomatic radiation pneumonitis (RP). Materials and Methods: In accordance with the retrospective study protocol approved by the institutional review board, 228 esophageal cancer patients who underwent FDG PET/CT before chemotherapy and RT were examined. RP symptoms were evaluated by using the Common Terminology Criteria for Adverse Events, version 4.0, from the consensus of five clinicians. By using the cumulative distribution of standardized uptake values (SUVs) within the lungs, those values greater than 80%-95% of the total lung voxels were determined for each patient. The effect of prechemotherapy and RT FDG uptake, dose, and patient or treatment characteristics on RP toxicity was studied by using logistic regression. Results: The study subjects were treated with three-dimensional conformal RT (n = 36), intensity-modulated RT (n = 135), or proton therapy (n = 57). Logistic regression analysis demonstrated elevated FDG uptake at pre-chemotherapy and RT was related to expression of RP symptoms. Study subjects with elevated 95% percentile of the SUV (SUV<inf>95</inf>) were more likely to develop symptomatic RP (P < .000012); each 0.1 unit increase in SUV<inf>95</inf> was associated with a 1.36-fold increase in the odds of symptomatic RP. Receiver operating characteristic (ROC) curve analysis resulted in area under the ROC curve of 0.676 (95% confidence interval: 0.58, 0.77), sensitivity of 60%, and specificity of 71% at the 1.17 SUV<inf>95</inf> threshold. CT imaging and dosimetric parameters were found to be poor predictors of RP symptoms. Conclusion: The SUV<inf>95</inf>, a biomarker of pretreatment pulmonary metabolic activity, was shown to be prognostic of symptomatic RP. Elevation in this pretreatment biomarker identifies patients at high risk for posttreatment symptomatic RP.

    Original languageEnglish (US)
    Pages (from-to)822-831
    Number of pages10
    JournalRadiology
    Volume275
    Issue number3
    DOIs
    StatePublished - Jun 1 2015

    Fingerprint

    Radiation Pneumonitis
    Pets
    Fluorodeoxyglucose F18
    Esophageal Neoplasms
    Radiotherapy
    ROC Curve
    Lung
    Biomarkers
    Logistic Models
    Proton Therapy
    Drug Therapy
    Research Ethics Committees
    Terminology
    Retrospective Studies
    Regression Analysis
    Confidence Intervals
    Sensitivity and Specificity

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Cite this

    Castillo, R., Pham, N., Castillo, E., Aso-Gonzalez, S., Ansari, S., Hobbs, B., ... Guerrero, T. M. (2015). Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis. Radiology, 275(3), 822-831. https://doi.org/10.1148/radiol.14140457

    Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis. / Castillo, Richard; Pham, Ngoc; Castillo, Edward; Aso-Gonzalez, Samantha; Ansari, Sobiya; Hobbs, Brian; Palacio, Diana; Skinner, Heath; Guerrero, Thomas M.

    In: Radiology, Vol. 275, No. 3, 01.06.2015, p. 822-831.

    Research output: Contribution to journalArticle

    Castillo, R, Pham, N, Castillo, E, Aso-Gonzalez, S, Ansari, S, Hobbs, B, Palacio, D, Skinner, H & Guerrero, TM 2015, 'Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis', Radiology, vol. 275, no. 3, pp. 822-831. https://doi.org/10.1148/radiol.14140457
    Castillo, Richard ; Pham, Ngoc ; Castillo, Edward ; Aso-Gonzalez, Samantha ; Ansari, Sobiya ; Hobbs, Brian ; Palacio, Diana ; Skinner, Heath ; Guerrero, Thomas M. / Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis. In: Radiology. 2015 ; Vol. 275, No. 3. pp. 822-831.
    @article{5a66f5c0516b4d3f88666633d85b2e0e,
    title = "Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis",
    abstract = "Purpose: To examine the association between pre-radiation therapy (RT) fluorine 18 fluorodeoxyglucose (FDG) uptake and post-RT symptomatic radiation pneumonitis (RP). Materials and Methods: In accordance with the retrospective study protocol approved by the institutional review board, 228 esophageal cancer patients who underwent FDG PET/CT before chemotherapy and RT were examined. RP symptoms were evaluated by using the Common Terminology Criteria for Adverse Events, version 4.0, from the consensus of five clinicians. By using the cumulative distribution of standardized uptake values (SUVs) within the lungs, those values greater than 80{\%}-95{\%} of the total lung voxels were determined for each patient. The effect of prechemotherapy and RT FDG uptake, dose, and patient or treatment characteristics on RP toxicity was studied by using logistic regression. Results: The study subjects were treated with three-dimensional conformal RT (n = 36), intensity-modulated RT (n = 135), or proton therapy (n = 57). Logistic regression analysis demonstrated elevated FDG uptake at pre-chemotherapy and RT was related to expression of RP symptoms. Study subjects with elevated 95{\%} percentile of the SUV (SUV95) were more likely to develop symptomatic RP (P < .000012); each 0.1 unit increase in SUV95 was associated with a 1.36-fold increase in the odds of symptomatic RP. Receiver operating characteristic (ROC) curve analysis resulted in area under the ROC curve of 0.676 (95{\%} confidence interval: 0.58, 0.77), sensitivity of 60{\%}, and specificity of 71{\%} at the 1.17 SUV95 threshold. CT imaging and dosimetric parameters were found to be poor predictors of RP symptoms. Conclusion: The SUV95, a biomarker of pretreatment pulmonary metabolic activity, was shown to be prognostic of symptomatic RP. Elevation in this pretreatment biomarker identifies patients at high risk for posttreatment symptomatic RP.",
    author = "Richard Castillo and Ngoc Pham and Edward Castillo and Samantha Aso-Gonzalez and Sobiya Ansari and Brian Hobbs and Diana Palacio and Heath Skinner and Guerrero, {Thomas M.}",
    year = "2015",
    month = "6",
    day = "1",
    doi = "10.1148/radiol.14140457",
    language = "English (US)",
    volume = "275",
    pages = "822--831",
    journal = "Radiology",
    issn = "0033-8419",
    publisher = "Radiological Society of North America Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Pre-radiation therapy fluorine 18 fluorodeoxyglucose pet helps identify patients with esophageal cancer at high risk for radiation pneumonitis

    AU - Castillo, Richard

    AU - Pham, Ngoc

    AU - Castillo, Edward

    AU - Aso-Gonzalez, Samantha

    AU - Ansari, Sobiya

    AU - Hobbs, Brian

    AU - Palacio, Diana

    AU - Skinner, Heath

    AU - Guerrero, Thomas M.

    PY - 2015/6/1

    Y1 - 2015/6/1

    N2 - Purpose: To examine the association between pre-radiation therapy (RT) fluorine 18 fluorodeoxyglucose (FDG) uptake and post-RT symptomatic radiation pneumonitis (RP). Materials and Methods: In accordance with the retrospective study protocol approved by the institutional review board, 228 esophageal cancer patients who underwent FDG PET/CT before chemotherapy and RT were examined. RP symptoms were evaluated by using the Common Terminology Criteria for Adverse Events, version 4.0, from the consensus of five clinicians. By using the cumulative distribution of standardized uptake values (SUVs) within the lungs, those values greater than 80%-95% of the total lung voxels were determined for each patient. The effect of prechemotherapy and RT FDG uptake, dose, and patient or treatment characteristics on RP toxicity was studied by using logistic regression. Results: The study subjects were treated with three-dimensional conformal RT (n = 36), intensity-modulated RT (n = 135), or proton therapy (n = 57). Logistic regression analysis demonstrated elevated FDG uptake at pre-chemotherapy and RT was related to expression of RP symptoms. Study subjects with elevated 95% percentile of the SUV (SUV95) were more likely to develop symptomatic RP (P < .000012); each 0.1 unit increase in SUV95 was associated with a 1.36-fold increase in the odds of symptomatic RP. Receiver operating characteristic (ROC) curve analysis resulted in area under the ROC curve of 0.676 (95% confidence interval: 0.58, 0.77), sensitivity of 60%, and specificity of 71% at the 1.17 SUV95 threshold. CT imaging and dosimetric parameters were found to be poor predictors of RP symptoms. Conclusion: The SUV95, a biomarker of pretreatment pulmonary metabolic activity, was shown to be prognostic of symptomatic RP. Elevation in this pretreatment biomarker identifies patients at high risk for posttreatment symptomatic RP.

    AB - Purpose: To examine the association between pre-radiation therapy (RT) fluorine 18 fluorodeoxyglucose (FDG) uptake and post-RT symptomatic radiation pneumonitis (RP). Materials and Methods: In accordance with the retrospective study protocol approved by the institutional review board, 228 esophageal cancer patients who underwent FDG PET/CT before chemotherapy and RT were examined. RP symptoms were evaluated by using the Common Terminology Criteria for Adverse Events, version 4.0, from the consensus of five clinicians. By using the cumulative distribution of standardized uptake values (SUVs) within the lungs, those values greater than 80%-95% of the total lung voxels were determined for each patient. The effect of prechemotherapy and RT FDG uptake, dose, and patient or treatment characteristics on RP toxicity was studied by using logistic regression. Results: The study subjects were treated with three-dimensional conformal RT (n = 36), intensity-modulated RT (n = 135), or proton therapy (n = 57). Logistic regression analysis demonstrated elevated FDG uptake at pre-chemotherapy and RT was related to expression of RP symptoms. Study subjects with elevated 95% percentile of the SUV (SUV95) were more likely to develop symptomatic RP (P < .000012); each 0.1 unit increase in SUV95 was associated with a 1.36-fold increase in the odds of symptomatic RP. Receiver operating characteristic (ROC) curve analysis resulted in area under the ROC curve of 0.676 (95% confidence interval: 0.58, 0.77), sensitivity of 60%, and specificity of 71% at the 1.17 SUV95 threshold. CT imaging and dosimetric parameters were found to be poor predictors of RP symptoms. Conclusion: The SUV95, a biomarker of pretreatment pulmonary metabolic activity, was shown to be prognostic of symptomatic RP. Elevation in this pretreatment biomarker identifies patients at high risk for posttreatment symptomatic RP.

    UR - http://www.scopus.com/inward/record.url?scp=84930863660&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84930863660&partnerID=8YFLogxK

    U2 - 10.1148/radiol.14140457

    DO - 10.1148/radiol.14140457

    M3 - Article

    VL - 275

    SP - 822

    EP - 831

    JO - Radiology

    JF - Radiology

    SN - 0033-8419

    IS - 3

    ER -